A Study of Ubenimex in Patients With Pulmonary Arterial Hypertension (WHO Group 1)
Status:
Completed
Trial end date:
2018-01-01
Target enrollment:
Participant gender:
Summary
Ubenimex is being developed for the treatment of pulmonary arterial hypertension (PAH) (World
Health Organization [WHO] Group 1) to improve exercise capacity and delay clinical worsening.
This proof-of-concept study is designed as a Phase 2, multicenter, randomized, double-blind,
placebo controlled study comparing ubenimex with placebo in patients with PAH (WHO Group 1)
and have a WHO/New York Heart Association (NYHA) Functional Classification (WHO/NYHA-FC) of
II or III. The Primary Objectives for the study are:
- To evaluate the efficacy of ubenimex in patients with PAH (WHO Group 1).
- To evaluate the safety and tolerability of ubenimex in patients with WHO Group 1 PAH.